Posts

Creative Biolabs Launches End-to-End AI-Driven Antibody Solutions to Accelerate Biotherapeutic Discovery and Engineering

on

Helmed by Sanofi vet, Bionyra emerges with $165M and three licensed I&I assets

on

Akeso takes center stage at ASCO 2026 as China biotech cements its global arrival

on

ASCO 2026: A battle of bispecifics, Eli Lilly’s big win and more

on

All eyes on Revolution, bispecific antibodies and more at ASCO26

on

Pfizer's Elrexfio Meets Phase III Primary Endpoint in Multiple Myeloma, Positioning Drug for Earlier-Line Use

on

Recent Pharmaceutical Industry Developments: AbbVie's China Engagement and Biologics Expansion

on

Sanofi Inks $2.56 Billion Autoimmune Bispecific Deal with Earendil Labs

on

MindWalk Announces B Cell Llama, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era

on

Boehringer Ingelheim Signs €1.05 Billion Deal for Simcere's Preclinical IBD Bispecific SIM0709

on

Caldera Therapeutics Launches with $112.5M Funding for China-Licensed IBD Bispecific Antibody

on

AbbVie Pays $650M Upfront to RemeGen for PD-1/VEGF Bispecific RC148 Rights Outside China

on

AbbVie Pays $650M Upfront to RemeGen for PD-1/VEGF Bispecific RC148 Rights Outside China

on

Sanofi returns to Dren Bio for another B‑cell depletion therapy with $100M upfront

on

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig in Advanced Triple-Negative Breast Cancer

on

Building the Next Generation of Biologics: Inside the Future of Protein Engineering

on

Crescent Biopharma and Kelun-Biotech Announce Reciprocal Licensing Pact for PD-1xVEGF and ADC Cancer Therapies

on

Roche Bags EU Nod for SC Formulation of Lunsumio, Re-Igniting Bispecific Battle with Tepkinly

on

MacroGenics Stops Bispecific Development; Third Arc Bio Signs $840M Licensing Deal with Adagene

on

Roche Signs $1B Licensing Deal with Qyuns Therapeutics for Preclinical COPD Bispecific Antibody

on